Revance Therapeutics, Inc.

NasdaqGM:RVNC Stock Report

Market Cap: US$382.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Revance Therapeutics Future Growth

Future criteria checks 1/6

Revance Therapeutics is forecast to grow earnings and revenue by 60.7% and 19.2% per annum respectively while EPS is expected to grow by 61% per annum.

Key information

60.7%

Earnings growth rate

60.98%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate19.2%
Future return on equityn/a
Analyst coverage

Good

Last updated22 Jan 2025

Recent future growth updates

Recent updates

Seeking Alpha • Sep 26

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Summary I initially downgraded Revance Therapeutics to a "Sell" in June due to financial struggles, competition, and potential cash flow issues by 2025. Revance's merger with Crown Labs at $6.66 per share, an 89% premium, temporarily boosted shares there are concerns surfacing about the deal's stability. The Teoxane dispute over RHA filler sales and marketing efforts could delay or jeopardize the merger, adding uncertainty to Revance's future. Despite potential positives, I maintain my "Sell" rating due to ongoing financial losses, competitive pressures, and merger uncertainties. Read the full article on Seeking Alpha
Seeking Alpha • Jun 20

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Summary Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock price has fallen by nearly 70% year-to-date, facing financial vulnerability and market skepticism. Wall Street remains skeptical about Revance's business model and forecasts, given it is facing competitive threats and ongoing disputes, making recovery uncertain. The company is in a financially perilous position and faces litigation from AbbVie accusing the company of misappropriating trade secrets. On the one hand, there is a risky contrarian bet with Revance shares down >90% in 15 months, but I am siding with Wall Street - the company faces a fight to survive in the midst of so many issues. Read the full article on Seeking Alpha
Analysis Article • Mar 04

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Those holding Revance Therapeutics, Inc. ( NASDAQ:RVNC ) shares would be relieved that the share price has rebounded...
Seeking Alpha • Feb 29

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Summary Revance Therapeutics, Inc. reported its Q4 and FY 23 earnings yesterday, February 28th - its stock price has been soaring as a result. The company is guiding for ~$280m of revenues in 2024 and narrowing losses - at least on a non-GAAP basis. I gave Revance stock a "sell" rating in my last note on the company at the end of November - I am upgrading my rating to Hold, for 2024. The company still faces major long term obstacles to success in my view, but management remains bullish and there are reasons to be more optimistic for 2024. Read the full article on Seeking Alpha
Analysis Article • Dec 28

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Revance Therapeutics, Inc. ( NASDAQ:RVNC ) shareholders are no doubt pleased to see that the share price has bounced...
Analysis Article • Nov 10

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

The analysts covering Revance Therapeutics, Inc. ( NASDAQ:RVNC ) delivered a dose of negativity to shareholders today...
Analysis Article • Aug 10

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jun 14

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales...
Analysis Article • Apr 17

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Jan 02

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Earnings and Revenue Growth Forecasts

NasdaqGM:RVNC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027497-9131855
12/31/2026415-3155268
12/31/2025333-102-35-248
12/31/2024264-168-108-538
9/30/2024257-303-195-191N/A
6/30/2024251-304-209-201N/A
3/31/2024240-325-221-213N/A
12/31/2023234-324-223-217N/A
9/30/2023204-292-210-204N/A
6/30/2023179-337-214-211N/A
3/31/2023153-341-204-202N/A
12/31/2022133-356-197-194N/A
9/30/2022109-274-214-208N/A
6/30/202299-263-210-203N/A
3/31/202290-274-216-208N/A
12/31/202178-281-232-222N/A
9/30/202163-297-247-239N/A
6/30/202147-303-250-242N/A
3/31/202129-292-218-210N/A
12/31/202015-282-183-179N/A
9/30/20204-249-152-150N/A
6/30/20200-209-129-126N/A
3/31/20200-186-141-138N/A
12/31/20190-159-109-106N/A
9/30/20191-155-108-104N/A
6/30/20193-146-103-97N/A
3/31/20194-143-112-105N/A
12/31/20184-143-111-104N/A
9/30/20183-138-107-102N/A
6/30/20181-136N/A-98N/A
3/31/20180-128N/A-85N/A
12/31/20170-121N/A-95N/A
9/30/20170-111N/A-80N/A
6/30/20170-99N/A-73N/A
3/31/20170-97N/A-65N/A
12/31/20160-89N/A-60N/A
9/30/20160-85N/A-63N/A
6/30/20160-86N/A-62N/A
3/31/20160-78N/A-58N/A
12/31/20150-73N/A-56N/A
9/30/20150-66N/A-48N/A
6/30/20150-60N/A-47N/A
3/31/20150-57N/A-47N/A
12/31/20140-63N/A-55N/A
9/30/20141-49N/A-60N/A
6/30/20141-48N/A-54N/A
3/31/20141-38N/A-62N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RVNC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RVNC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RVNC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RVNC's revenue (19.2% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: RVNC's revenue (19.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RVNC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/05 22:49
End of Day Share Price 2025/02/05 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revance Therapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MarisBMO Capital Markets Equity Research
Louise ChenCantor Fitzgerald & Co.
Donald EllisCitizens JMP Securities, LLC